Monitored Anesthesia Care Under a Combination of Low-Dose Remimazolam Infusion and Flumazenil Antagonism: A Case Report

Remimazolam is a novel benzodiazepine known for its short-acting properties. The safe use of flumazenil antagonism following remimazolam infusion remains a subject of debate. We present a case of monitored anesthesia care managed to be safe through low-dose remimazolam infusion and flumazenil antago...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamata, Kotoe, Masui, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Anesthesiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630703/
https://www.ncbi.nlm.nih.gov/pubmed/38021893
http://dx.doi.org/10.7759/cureus.46728
Descripción
Sumario:Remimazolam is a novel benzodiazepine known for its short-acting properties. The safe use of flumazenil antagonism following remimazolam infusion remains a subject of debate. We present a case of monitored anesthesia care managed to be safe through low-dose remimazolam infusion and flumazenil antagonism. Pharmacokinetic simulations revealed that low-dose remimazolam was practically useful as one of the components of multimodal sedation/analgesia. Subsequent sedation with the readministration of remimazolam after a dose of flumazenil could also be attained.

Ejemplares similares